Jnana Therapeutics Inc. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatohepatitis, phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism spectrum disorders, among others.